Annual Operating Expenses
$4.30 B
+$814.50 M+23.37%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual total operating expenses is currently $4.30 billion, with the most recent change of +$814.50 million (+23.37%) on 31 December 2023. During the last 3 years, it has risen by +$1.70 billion (+65.37%). VRTX annual operating expenses is now at all-time high.VRTX Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Expenses
$1.25 B
-$91.10 M-6.80%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly total operating expenses is currently $1.25 billion, with the most recent change of -$91.10 million (-6.80%) on 30 September 2024. Over the past year, it has increased by +$173.90 million (+16.19%). VRTX quarterly operating expenses is now -27.49% below its all-time high of $1.72 billion, reached on 31 December 2023.VRTX Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +23.4% | +16.2% |
| 3 y3 years | +65.4% | +80.3% |
| 5 y5 years | +117.8% | +74.3% |
VRTX Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +65.4% | -27.5% | +80.3% |
| 5 y | 5 years | at high | +117.8% | -27.5% | +103.6% |
| alltime | all time | at high | >+9999.0% | -27.5% | >+9999.0% |
Vertex Pharmaceuticals Incorporated Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.25 B(-6.8%) |
| June 2024 | - | $1.34 B(+18.3%) |
| Mar 2024 | - | $1.13 B(-34.2%) |
| Dec 2023 | $4.30 B(+23.4%) | $1.72 B(+60.3%) |
| Sept 2023 | - | $1.07 B(+2.4%) |
| June 2023 | - | $1.05 B(+6.6%) |
| Mar 2023 | - | $983.70 M(-8.7%) |
| Dec 2022 | $3.48 B(+25.5%) | $1.08 B(+20.8%) |
| Sept 2022 | - | $891.80 M(+9.4%) |
| June 2022 | - | $815.40 M(-0.1%) |
| Mar 2022 | - | $816.30 M(-14.0%) |
| Dec 2021 | $2.78 B(+6.8%) | $949.50 M(+37.2%) |
| Sept 2021 | - | $691.90 M(-56.8%) |
| June 2021 | - | $1.60 B(+147.1%) |
| Mar 2021 | - | $648.10 M(-4.5%) |
| Dec 2020 | $2.60 B(+7.7%) | $678.43 M(+0.1%) |
| Sept 2020 | - | $678.05 M(+10.7%) |
| June 2020 | - | $612.73 M(-2.9%) |
| Mar 2020 | - | $630.79 M(-6.6%) |
| Dec 2019 | $2.41 B(+22.2%) | $675.25 M(-5.6%) |
| Sept 2019 | - | $715.62 M(+33.6%) |
| June 2019 | - | $535.59 M(+10.1%) |
| Mar 2019 | - | $486.54 M(-17.7%) |
| Dec 2018 | $1.97 B(+8.4%) | $591.09 M(+26.4%) |
| Sept 2018 | - | $467.81 M(-1.5%) |
| June 2018 | - | $474.83 M(+7.8%) |
| Mar 2018 | - | $440.36 M(-0.2%) |
| Dec 2017 | $1.82 B(+23.0%) | $441.46 M(-23.3%) |
| Sept 2017 | - | $575.66 M(+38.1%) |
| June 2017 | - | $416.70 M(+7.7%) |
| Mar 2017 | - | $386.89 M(+8.0%) |
| Dec 2016 | $1.48 B(+7.9%) | $358.36 M(-5.3%) |
| Sept 2016 | - | $378.43 M(-1.1%) |
| June 2016 | - | $382.66 M(+6.0%) |
| Mar 2016 | - | $361.07 M(-11.2%) |
| Dec 2015 | $1.37 B(+18.2%) | $406.73 M(+17.5%) |
| Sept 2015 | - | $346.06 M(+8.7%) |
| June 2015 | - | $318.25 M(+5.6%) |
| Mar 2015 | - | $301.46 M(+7.7%) |
| Dec 2014 | $1.16 B(-6.2%) | $279.99 M(+5.2%) |
| Sept 2014 | - | $266.16 M(-11.8%) |
| June 2014 | - | $301.93 M(-3.5%) |
| Mar 2014 | - | $312.83 M(+0.4%) |
| Dec 2013 | $1.24 B(+3.3%) | $311.52 M(+1.8%) |
| Sept 2013 | - | $305.87 M(-7.0%) |
| June 2013 | - | $328.98 M(+5.8%) |
| Mar 2013 | - | $310.97 M(+11.4%) |
| Dec 2012 | $1.20 B(+8.1%) | $279.17 M(-6.3%) |
| Sept 2012 | - | $297.85 M(-5.2%) |
| June 2012 | - | $314.06 M(+2.1%) |
| Mar 2012 | - | $307.52 M(-0.3%) |
| Dec 2011 | $1.11 B(+34.3%) | $308.32 M(+2.9%) |
| Sept 2011 | - | $299.71 M(+10.9%) |
| June 2011 | - | $270.27 M(+17.4%) |
| Mar 2011 | - | $230.13 M(-0.5%) |
| Dec 2010 | $825.22 M(+21.3%) | $231.37 M(+5.5%) |
| Sept 2010 | - | $219.29 M(+11.9%) |
| June 2010 | - | $196.00 M(+9.8%) |
| Mar 2010 | - | $178.56 M(+6.4%) |
| Dec 2009 | $680.47 M(+10.1%) | $167.80 M(-0.5%) |
| Sept 2009 | - | $168.70 M(-1.8%) |
| June 2009 | - | $171.86 M(-0.1%) |
| Mar 2009 | - | $172.10 M(+1.9%) |
| Dec 2008 | $618.20 M(+3.4%) | $168.82 M(+7.4%) |
| Sept 2008 | - | $157.16 M(+0.7%) |
| June 2008 | - | $156.02 M(+14.5%) |
| Mar 2008 | - | $136.21 M(-1.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $597.78 M(+39.2%) | $138.79 M(-7.7%) |
| Sept 2007 | - | $150.37 M(-5.7%) |
| June 2007 | - | $159.51 M(+7.0%) |
| Mar 2007 | - | $149.12 M(+19.3%) |
| Dec 2006 | $429.57 M(+46.8%) | $124.98 M(+12.7%) |
| Sept 2006 | - | $110.89 M(+5.0%) |
| June 2006 | - | $105.62 M(+19.9%) |
| Mar 2006 | - | $88.08 M(+8.8%) |
| Dec 2005 | $292.53 M(+24.9%) | $80.97 M(+8.9%) |
| Sept 2005 | - | $74.33 M(+5.9%) |
| June 2005 | - | $70.17 M(+4.6%) |
| Mar 2005 | - | $67.06 M(+1.8%) |
| Dec 2004 | $234.30 M(-1.9%) | $65.90 M(+11.0%) |
| Sept 2004 | - | $59.39 M(+3.1%) |
| June 2004 | - | $57.61 M(+12.1%) |
| Mar 2004 | - | $51.40 M(-12.6%) |
| Dec 2003 | $238.72 M(-0.3%) | $58.77 M(-0.5%) |
| Sept 2003 | - | $59.06 M(-43.8%) |
| June 2003 | - | $105.05 M(<-9900.0%) |
| Mar 2003 | - | -$112.00 K(-100.2%) |
| Dec 2002 | $239.39 M(+21.6%) | $57.83 M(-9.0%) |
| Sept 2002 | - | $63.55 M(+6.1%) |
| June 2002 | - | $59.89 M(+3.1%) |
| Mar 2002 | - | $58.12 M(+5.1%) |
| Dec 2001 | $196.80 M(+36.9%) | $55.29 M(+10.1%) |
| Sept 2001 | - | $50.22 M(+32.3%) |
| June 2001 | - | $37.97 M(+13.0%) |
| Mar 2001 | - | $33.62 M(-41.9%) |
| Dec 2000 | $143.79 M(+37.5%) | $57.81 M(+91.4%) |
| Sept 2000 | - | $30.20 M(+5.6%) |
| June 2000 | - | $28.59 M(+5.3%) |
| Mar 2000 | - | $27.16 M(-4.7%) |
| Dec 1999 | $104.60 M(+28.5%) | $28.50 M(+16.3%) |
| Sept 1999 | - | $24.50 M(-5.4%) |
| June 1999 | - | $25.91 M(+1.2%) |
| Mar 1999 | - | $25.60 M(+0.4%) |
| Dec 1998 | $81.40 M(+22.2%) | $25.50 M(+18.1%) |
| Sept 1998 | - | $21.60 M(+20.7%) |
| June 1998 | - | $17.90 M(+9.1%) |
| Mar 1998 | - | $16.40 M(-12.3%) |
| Dec 1997 | $66.60 M(+8.6%) | $18.70 M(-7.4%) |
| Sept 1997 | - | $20.20 M(+42.3%) |
| June 1997 | - | $14.20 M(+6.8%) |
| Mar 1997 | - | $13.30 M(-48.8%) |
| Dec 1996 | $61.30 M(+17.2%) | $26.00 M(+134.2%) |
| Sept 1996 | - | $11.10 M(-9.8%) |
| June 1996 | - | $12.30 M(+3.4%) |
| Mar 1996 | - | $11.90 M(+3.5%) |
| Dec 1995 | $52.30 M(+19.4%) | $11.50 M(+1.8%) |
| Sept 1995 | - | $11.30 M(-35.4%) |
| June 1995 | - | $17.50 M(+45.8%) |
| Mar 1995 | - | $12.00 M(-0.8%) |
| Dec 1994 | $43.80 M(+43.1%) | $12.10 M(+9.0%) |
| Sept 1994 | - | $11.10 M(0.0%) |
| June 1994 | - | $11.10 M(+14.4%) |
| Mar 1994 | - | $9.70 M(-7.6%) |
| Dec 1993 | $30.60 M(+84.3%) | $10.50 M(+28.0%) |
| Sept 1993 | - | $8.20 M(+26.2%) |
| June 1993 | - | $6.50 M(+25.0%) |
| Mar 1993 | - | $5.20 M(+13.0%) |
| Dec 1992 | $16.60 M(+56.6%) | $4.60 M(+7.0%) |
| Sept 1992 | - | $4.30 M(+230.8%) |
| June 1992 | - | $1.30 M(-63.9%) |
| Mar 1992 | - | $3.60 M(+20.0%) |
| Dec 1991 | $10.60 M(+65.6%) | $3.00 M(+15.4%) |
| Sept 1991 | - | $2.60 M(0.0%) |
| June 1991 | - | $2.60 M |
| Dec 1990 | $6.40 M | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual total operating expenses?
- What is the all time high annual operating expenses for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual operating expenses year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly operating expenses year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual total operating expenses?
The current annual operating expenses of VRTX is $4.30 B
What is the all time high annual operating expenses for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual total operating expenses is $4.30 B
What is Vertex Pharmaceuticals Incorporated annual operating expenses year-on-year change?
Over the past year, VRTX annual total operating expenses has changed by +$814.50 M (+23.37%)
What is Vertex Pharmaceuticals Incorporated quarterly total operating expenses?
The current quarterly operating expenses of VRTX is $1.25 B
What is the all time high quarterly operating expenses for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly total operating expenses is $1.72 B
What is Vertex Pharmaceuticals Incorporated quarterly operating expenses year-on-year change?
Over the past year, VRTX quarterly total operating expenses has changed by +$173.90 M (+16.19%)